[INNOVATION UPDATE] Sodium Oxybate Extended-Release (Lumryz) to Treat Pediatric Narcolepsy Narcolepsy is a chronic neurologic disorder that disrupts the brain’s ability to regulate sleep-wake cycles. Sodium oxybate, also known as gamma-hydroxybutyrate, was approved by the US Food and Drug Administration in 2002 to treat adults with narcolepsy and in 2018 to treat children 7 years of age or older. Lumryz is a once-nightly extended-release formulation of sodium oxybate previously available only to adult patients. This indication was expanded on October 17, 2024, to include children 7 years of age or older based on positive clinical data in this age range. Compared with twice nightly dosing of conventional sodium oxybate formulations, this extended-release option may improve quality of life for children with narcolepsy and their caregivers. Want to learn more about this novel treatment? View the Emerging Health Care Innovation Brief: https://hubs.la/Q02-hBhY0 #narcolepsy #chronicdiseases #neurologicdisorders #neurology #patientcare #healthcare #innovation #horizonscanning #ECRI
